Abstract：
Patients with type 2 diabetes (T2D) are at an increased risk of morbidity and mortality of coronavirus disease 2019 (COVID-19). Data on the antibody response to COVID-19 vaccines in T2D patients are less studied. This study aimed to evaluate IgG antibody response to inactivated COVID-19 vaccines in hospitalized T2D patients. Hospitalized patients with no history of COVID-19 and received two doses of inactivated COVID-19 vaccines (Sinopharm or CoronaVac) were included in this study from March to October 2021. SARS-CoV-2 specific IgG antibodies were measured 14-60 days after the second vaccine dose. A total of 209 participants, 96 with T2D and 113 non-diabetes patients, were included. The positive rate and median titer of IgG antibody against receptor-binding domain (anti-RBD) of spike (S) protein of SARS-CoV-2 in T2D group were lower than in control group (67.7% vs 83.2%, p = .009; 12.93 vs 17.42 AU/ml, p = .014) respectively. Similarly, seropositivity and median titers of IgG antibody against the nucleocapsid (N) and S proteins of SARS-CoV-2 (anti-N/S) in T2D group were lower than in control group (68.8% vs 83.2%, p = .032; 18.81 vs 29.57 AU/mL, p = .012) respectively. After adjustment for age, sex, BMI, vaccine type, days after the second vaccine dose, hypertension, kidney disease, and heart disease, T2D was identified as an independent risk factor for negative anti-RBD and anti-N/S seropositivity, odd ratio 0.42 (95% confidence interval 0.19, 0.89) and 0.42 (95% CI 0.20, 0.91), respectively. T2D is associated with impaired antibody response to inactivated COVID-19 vaccine.
摘要：
2型糖尿病（T2D）患者2019年冠状病毒病（COVID-19）的发病和死亡风险增加。关于T2D患者对COVID-19疫苗的抗体反应的数据研究较少。本研究旨在评估住院T2D患者对灭活COVID-19疫苗的IgG抗体反应。这项研究包括2021年3月至10月没有COVID-19病史并接受两剂灭活COVID-19疫苗（国药或CoronaVac）的住院患者。在第二次疫苗剂量后14-60天测量SARS-CoV-2特异性IgG抗体。共有209人参加，96例T2D和113例非糖尿病患者，包括在内。T2D组SARS-CoV-2刺突（S）蛋白的抗受体结合域（抗RBD）IgG抗体阳性率和中位滴度均低于对照组（67.7％vs83.2％，p=.009；12.93对17.42AU/ml，p=.014）分别。同样，T2D组针对SARS-CoV-2（抗N/S）的核衣壳（N）和S蛋白的IgG抗体的血清阳性和中位滴度均低于对照组（68.8％vs83.2％，p=.032；18.81对29.57AU/mL，p=.012）分别。调整后的年龄，性别,BMI,疫苗类型,第二次疫苗接种后几天，高血压,肾病,还有心脏病,T2D被确定为抗RBD阴性和抗N/S血清阳性的独立危险因素，奇数比0.42(95%置信区间0.19，0.89)和0.42(95%CI0.20，0.91)，分别。T2D与对灭活COVID-19疫苗的抗体反应受损有关。
